螺内酯对血液透析患者左心室质量影响的随机对照试验
这项安慰剂对照随机试验纳入97例血液透析患者,评估螺内酯50mg/日对左心室质量指数(LVMi)的影响。40周时,螺内酯组与安慰剂组LVMi无显著变化(-2.86±11.87 vs. 0.41±10.84 g/m2),次要终点(血压、射血分数、6分钟步行距离、NYHA分级)也无差异。螺内酯组中度高钾血症(透析前血钾6.0-6.5 mmol/L)事件更多(155 vs. 80次),但重度高钾血症(≥6.5 mmol/L)未增加(14 vs. 24次)。
要点
- 螺内酯50mg/日未改善血液透析患者左心室质量指数。
- 螺内酯组中度高钾血症事件增多,但重度高钾血症未增加。
- 两组残余肾功能和24小时动态血压无显著差异。
核心结论
- 螺内酯50mg/日治疗40周未改变血液透析患者的左心室质量指数、心脏功能或血压。
- 螺内酯增加中度高钾血症频率,但未增加重度高钾血症。
研究设计与样本
- 安慰剂对照、平行组随机对照试验,纳入97例血液透析患者(23%女性,平均年龄60.3岁),随机接受螺内酯50mg每日一次(n=50)或安慰剂(n=47)。
- 主要疗效终点为基线至40周左心室质量指数(LVMi)的变化,通过心脏磁共振成像测定。
主要发现
- 螺内酯组与安慰剂组LVMi变化无显著差异(-2.86±11.87 vs. 0.41±10.84 g/m2)。
- 次要终点(24小时动态收缩压/舒张压、左心室射血分数、6分钟步行试验距离、NYHA功能分级)两组间无差异。
- 中度高钾血症(透析前血钾6.0-6.5 mmol/L)事件螺内酯组155次 vs. 安慰剂组80次,重度高钾血症(≥6.5 mmol/L)事件14次 vs. 24次。
- 残余尿量和实测肾小球滤过率变化两组间无差异。
- 螺内酯组无死亡,安慰剂组4例死亡。
临床怎么用
- 对于血液透析患者,螺内酯50mg/日不应常规用于改善左心室质量或心脏功能。
- 使用螺内酯时需监测透析前血钾,警惕中度高钾血症发生。
局限性
- 样本量较小(97例),可能不足以检测出LVMi的微小变化。
- 研究仅评估50mg/日螺内酯40周的效果,其他剂量或更长疗程未涉及。
- 主要终点为影像学替代指标,未评估硬终点如心血管事件或死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mineralocorticoid receptor antagonists have beneficial effects on left ventricular remodeling, cardiac fibrosis, and arrhythmia in heart failure, but efficacy and safety in dialysis patients is less clear. We evaluated the effect of spironolactone on left ventricular mass (LVM), an independent predictor of all-cause and cardiovascular mortality, in hemodialysis patients. In this placebo-controlled, parallel-group trial, 97 hemodialysis patients (23% female; mean age 60.3 years) were randomized to spironolactone 50 mg once daily (n=50) or placebo (n=47). The primary efficacy endpoint was change in LVM index (LVMi) from baseline to 40 weeks as determined by cardiac magnetic resonance imaging. Safety endpoints were development of hyperkalemia and change in residual renal function. There was no significant change in LVMi in participants randomized to spironolactone compared to placebo (-2.86±11.87 vs. 0.41±10.84 g/m2). There was also no difference in the secondary outcomes of mean 24-hour systolic or diastolic ambulatory blood pressure, left ventricular ejection fraction, 6-minute walk test distance, or New York Heart Association functional class. Moderate hyperkalemia (pre-dialysis potassium levels of 6.0-6.5 mmol/L) was more frequent with spironolactone treatment (155 vs. 80 events), but severe hyperkalemia (≥6.5 mmol/L) was not (14 vs. 24 events). Changes in residual urine volume and measured glomerular filtration rate did not differ between groups. There were no deaths in the spironolactone group and 4 deaths in the placebo group. Thus, treatment with 50 mg spironolactone did not change left ventricular mass index, cardiac function, or blood pressure in hemodialysis patients. Spironolactone increased the frequency of moderate hyperkalemia, but did not increase severe hyperkalemia.
引用
- Hammer F, Malzahn U, Donhauser J, et al. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int. 2019. PMID: 30712923. doi:10.1016/j.kint.2018.11.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。